Document Detail

Metformin therapy in diabetes: the role of cardioprotection.
MedLine Citation:
PMID:  23423523     Owner:  NLM     Status:  In-Data-Review    
In patients with diabetes mellitus, the incidence of cardiovascular disease is increased, and the outcome following cardiovascular events is worse. The antihyperglycemic drug metformin appears to limit cardiovascular death in patients with type 2 diabetes. Indeed, preclinical studies have demonstrated that metformin limits (myocardial) ischemia and reperfusion injury, independent from its glucose-lowering effect. This cardioprotection is mediated by activation of the Reperfusion Injury Salvage Kinase (RISK) pathway, activation of AMPK and by an increased formation of adenosine. In addition, metformin can modulate several cardiovascular risk factors and reduces the development of heart failure in murine models. Consequently, treatment with metformin might potentially improve cardiovascular outcome in patients at risk for myocardial ischemia, even if these patients do not have diabetes. In the current paper, we focus on the direct cardioprotective actions of metformin and the mechanisms that underlie these effects.
Saloua El Messaoudi; Gerard A Rongen; Niels P Riksen
Related Documents :
24918743 - Effects of il-1β-blocking therapies in type 2 diabetes mellitus: a quantitative system...
24746173 - Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 ...
1864483 - Insulin treatment prevents diabetes mellitus but not thyroiditis in rt6-depleted diabet...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current atherosclerosis reports     Volume:  15     ISSN:  1534-6242     ISO Abbreviation:  Curr Atheroscler Rep     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-02-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897685     Medline TA:  Curr Atheroscler Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  314     Citation Subset:  IM    
Department of Pharmacology-Toxicology 149, Radboud University Nijmegen Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Medical management of stable coronary atherosclerosis.
Next Document:  The cholesterol emboli syndrome in atherosclerosis.